Targeting MDR1 Gene: Synthesis and Cellular Study of Modified Daunomycin-Triplex-Forming Oligonucleotide Conjugates Able to Inhibit Gene Expression in Resistant Cell Lines

Vérène Stierlé, Maria Duca, Ludovic Halby, Catherine Senamaud-Beaufort, Massimo L. Capobianco, Alain Laigle, Béatrice Jollès, and Paola B. Arimondo

La laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7033, Université Pierre et Marie Curie-Paris 6, Paris, France (V.S., A.L., B.J.); Université Paris 13, Bobigny, France (V.S., A.L., B.J.); Laboratoire de Régulation et Dynamiques des Génotomes Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5153, Muséum national d'Histoire naturelle USM0503 (M.D., L.H., C.S.-B., P.B.A.); Institut National de la Santé et de la Recherche Médicale UR565, Paris cedex 05, France (M.D., L.H., C.S.-B., P.B.A.); and Istituto per la Sintesi Organica e la Fotorreattività del Consiglio Nazionale delle Ricerche, Bologna, Italy (M.L.C.)

Received September 20, 2007; accepted February 25, 2008

ABSTRACT

Reversal of the multidrug-resistant (MDR) phenotype is very important for chemotherapy success. In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance. We show that upon conjugation to triplex-forming oligonucleotides, it is possible to address DNM in resistant cells (MCF7-R and NIH-MDR-G185). The oligonucleotide moiety of the conjugate changes the cellular penetration properties of the antitumor agent that is no more the target of P-gp in resistant cells. We observe an accumulation of conjugated DNM in cells up to 72 h. For more efficient delivery in the cells' nuclei, transfectant agents must be used. In addition, the conjugate recognizes a sequence located in exon 3 of MDR1, and it inhibits its gene expression as measured both by Western blot and by reverse transcription-polymerase chain reaction.

Conventional cancer chemotherapy is seriously limited by the multidrug resistance (MDR) commonly acquired by tumor cells (Pérez-Tomás, 2006). One mechanism by which a living cell can achieve multiple resistances is via the active efflux by MDR proteins of a broad range of anticancer drugs through the cellular membrane. MDR1 (ABCB1) overexpression is one form of MDR; the gene encodes for the 170-kDa P-glycoprotein (P-gp), a transmembrane pump that causes efflux of organic compounds out of cells. Among drugs that commonly act as substrates of P-gp is, for example, the family of the anthracyclines such as daunomycin (DNM). A consistent amount of research has been devoted to MDR reversal. Many compounds able to modulate this phenotype in vitro by inhibiting the efflux pump activity of P-gp have been found. However, their clinical application is limited because of their high toxicity. Therefore, attention has been drawn to the selective down-regulation of MDR1 expression through antisense (Quattrone et al., 1994; Bertram et al., 1995; Alahari et al., 1996; Liu et al., 1996), and, more recently, small interfering RNA (siRNA) (Nieth et al., 2003; Wu et al., 2003; Duan et al., 2004).

In addition to these approaches, the antigene strategy can also be used to specifically modulate gene expression. It is based on triplex-forming oligonucleotides (TFOs) that bind DNA and target specifically purine-rich sequences by forming a DNA triple helix. The high frequency of triplex target sequences in the genome, together with the high sequence

ABBRvIATIONS: MDR, multidrug resistance; P-gp, P-glycoprotein; DNM, daunomycin; siRNA, small interfering RNA; TFO, triplex-forming oligonucleotide; P, 5-propynyluracils; M, 5-methylcytosines; LNA, locked nucleic acid; HPLC, high-performance liquid chromatography; AS, antisense; MS, mass spectrometry; C50, concentration at which 50% of triplex is formed; RT-PCR, reverse transcription-polymerase chain reaction; OFA, Oligofectamine; PBS, phosphate-buffered saline; bp, base pair(s); Tm, melting temperature; R, oligopurine strand of the duplex; Y, oligopyrimidine strand of the duplex.
specificity of TFOs, makes these molecules effective tools to modulate in a selective manner gene expression via transcriptional repression, mutagenesis, and recombination. In fact, triplex approaches have been applied with success in various experimental models, including living cells and animals, and they may provide the means for the design of novel gene targeted therapeutics (Hurley, 2002).

The strategy has been already used to target the MDR1 gene obtaining inhibition of transcription as revealed by a meaningful reduction of mRNA amount (Scagagente et al., 1994; Labroille et al., 1998; Morassutti et al., 1999). However, no detectable functional reversal of the drug was observed after TFO treatment. In the present study, we conceived, synthesized, and investigated for their biological activity new TFO conjugates of the anticancer drug DNM directed against MDR1. DNM belongs to the family of the anthracyclines, which are among the most commonly used and effective anticancer drugs; they are used in breast cancer, lymphomas, and mainly in acute leukemias (Hande, 2003). In the past, TFO conjugates of anthracycline derivatives have been synthesized to target an oligopyrimidine-oligouridine sequence in exon 2 of MDR1 (Garbese et al., 1997; Capobianco et al., 2001), and, recently, in the P2 promoter of c-myc (Carbone et al., 2004; Napoli et al., 2006). It is noteworthy that DNM is also the target of the P-gp pump, and, upon overexpression of MDR1, resistance to DNM is observed, which is very hampering for its use in chemotherapy. In a general effort to reverse multidrug resistance and to find more active and specific anticancer drugs, we show here for the first time that it is possible to combine (and take advantage of) three different properties of DNM conjugates: 1) DNM biological activity, 2) oligonucleotide chemical properties, and 3) ability of the TFO to specifically inhibit gene expression. These three properties allowed us to 1) inhibit the efflux of DNM conjugates from resistant cells (cells overexpressing the gene MDR1) and at the same time to 2) reduce the expression of both P-gp mRNA and protein levels in these cells. We exploited the oligopyrimidine-oligouridine tract in exon 3 of the MDR1 gene described previously (Scagagente et al., 1994; Labroille et al., 1998; Morassutti et al., 1999), and we conceived modified DNM oligonucleotides able to specifically target this sequence. The use of different types of oligonucleotides (parallel and antiparallel) containing different chemical modifications, such as thyminides substituted by 5-propynyluracils (P), cytosines substituted by 5-methylcytosines (M), and locked nucleic acids (LNAs), allowed us to choose the best chemistry to obtain a stable triplex. DNM was coupled to oligonucleotides, forming stable triplexes, and locked nucleic acids (LNAs), allowed us to choose the best chemistry to obtain a stable triplex. The concentration of conjugate or TFO necessary to obtain 50% of triplex was calculated, and a mean value corresponding to three to five different experiments is reported.

Materials and Methods

Methods. For all oligonucleotide conjugates, mass determination was accomplished by electrospray ionization on a QSTAR pulsar I (Applied Biosystems, Courtaboeuf, France) and HPLC purifications were performed on an Agilent 1100 series system (Agilent Technologies, Massy, France) using a Xterra reversed-phase C18 column (4.6 × 50 mm; 2.5 μm). Absorbance spectrophotometry was performed on a UVikon 860 (Kontron Instruments, Watford, Herts, UK).

Materials. All chemicals were purchased from Aldrich Chemical Co. (Milwaukee, WI). All solvents were of analytical grade.

Oligonucleotides. Oligonucleotides PM, PM-NH2, SC, and GTI–4 were purchased from Eurogentec (Seraing, Belgium). LNAs were synthesized accordingly to a procedure described previously (Capobianco et al., 2005). The iodoalkyl derivative of daunomycin was initially prepared with the amino group of daunomycin protected as trifluoroacetate. Synthesis of the daunomycin-conjugated oligonucleotides was then accomplished by reaction of the iodoalkyl derivative of daunomycin with phosphodiester oligonucleotides carrying a 3'- or 5'-thioephosphate group. After extraction of the excess of iodoalkyl derivative, the trifluoroacetetyl protecting group was removed from the amino group of the daunomycin by mild basic hydrolysis. The daunomycin-conjugated oligonucleotides were then purified by reverse-phase HPLC. The structure of conjugates was confirmed by MS and UV-visible spectroscopy. A mean yield of 65% was obtained: PM-DNM MS (ES+) m/z: 5452 [M-H]- (calculated: 5453); PM-DNM MS (ES+) m/z: 5448 [M-H]- (calculated: 5453); and SC-DNM MS (ES+) m/z: 5277 [M-H]- (calculated: 5278).

Synthesis. Daunomycin-conjugated oligonucleotides PM, SC, and LNAs, with a hexamethylene bridge connecting the 5’ end of the oligonucleotides to the O-4 position in the D ring of the anthraquinone, were synthesized and sequenced accordingly to a procedure described previously (Capobianco et al., 2005). The iodoalkyl derivative of daunomycin was initially prepared with the amino group of daunomycin protected as trifluoroacetate. Synthesis of the daunomycin-conjugated oligonucleotides was then accomplished by reaction of the iodoalkyl derivative of daunomycin with phosphodiester oligonucleotides carrying a 3'- or 5'-thioephosphate group. After extraction of the excess of iodoalkyl derivative, the trifluoroacetetyl protecting group was removed from the amino group of the daunomycin by mild basic hydrolysis. The daunomycin-conjugated oligonucleotides were then purified by reverse-phase HPLC. The structure of conjugates was confirmed by MS and UV-visible spectroscopy. A mean yield of 65% was obtained: PM-DNM MS (ES+) m/z: 5452 [M-H]- (calculated: 5453); PM-DNM MS (ES+) m/z: 5448 [M-H]- (calculated: 5453); and SC-DNM MS (ES+) m/z: 5277 [M-H]- (calculated: 5278).

Gel Retardation Assay. The oligopyrimidine strand of the duplex was 5’ end-labeled with [γ-32P]ATP (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) by T4 polynucleotide kinase (New England Biolabs, Ipswich, MA) according to the manufacturer’s instructions. Increasing concentrations (10 nM–5 μM) of the triplex-forming oligonucleotides were added to 10 nM concentrations of the radiolabeled duplex in 10 mM MgCl2, 50 mM NaCl, 50 mM HEPES, pH 7.2, 10% sucrose, and 0.5 mg/ml tRNA followed by sample incubation at 37°C for 2 to 48 h. Electrophoresis was performed on a nondenaturing 15% polyacrylamide gel containing 10 mM MgCl2 and 50 mM HEPES, pH 7.2, at 37°C. To quantify the formation of the triplex, gels were scanned with a Typhoon 9410 (GE Healthcare). The concentration of conjugate or TFO necessary to obtain 50% of formed triplex (C50) was calculated, and a mean value corresponding to three to five different experiments is reported.

UV Melting Experiments. A UVikon 940 spectrophotometer (Kontron Instruments) with 1-cm optical pathlength quartz cuvettes was used to study thermal denaturation and renaturation of triplex formation. The cell holder was thermostated with an 80% water/20% ethylene glycol circulating liquid. Sample temperature was decreased from 60°C to 0°C, and then it was increased back to 60°C at 0.2°C/min, with absorption readings at 245, 260, 295, 520, and 620 nm taken every 1 to 1.2°C during three cycles. Samples were maintained at each extreme temperature for an additional 10 min. Experimental conditions were as described in the figure and table legends. All samples contained 10 mM sodium cacodylate at the indicated pH, 50 mM NaCl, and 10 mM MgCl2.

Oligonucleotides concentration was 1 μM, 1.05 μM, and 1.2 μM TFO in the triplex experiments.
Cells and Transfection. MCF7-S (the parental human mammary adenocarcinoma cell line) and MCF7-R (the doxorubicin-resistant line) were a gift from M. F. Poupon (Institut Curie, Paris, France). NIH-3T3 cells were obtained from the American Type Culture Collection (Manassas, VA). NIH-MDR-G185 cells stably transfected with a plasmid containing the human MDR1 gene (pSK1 MDR) were a gift from M. Gottesman (National Cancer Institute, Bethesda, MD). Cells were grown in RPMI 1640 medium supplemented with 10% decomplemented fetal bovine serum, 50 U/ml penicillin, 50 μg/ml streptomycin, and 2 mM glutamine in a 5% CO2 atmosphere. Transfection with Oligofectamine (OFA) (Invitrogen, Paisley, UK) or SuperFect (QIAGEN, Hilden, Germany) was carried out as directed by the manufacturers. Cells (3 × 10^5/well) were plated in six-well plates. They were transfected at 30 to 40% confluence. The final concentrations in oligonucleotide were 500 nM for OFA and 10 nM for siRNA.

Fluorescence Imaging and Microspectrofluorometry. MCF7-R or NIH-3T3 cells were washed with ice-cold phosphate-buffered saline (PBS), and then they were observed by fluorescence microscopy on an Optiphot-2 epifluorescence microscope (Nikon, Tokyo, Japan) 24, 48, or 72 h after treatment with the DNM conjugates (alone or transfected with OFA). Nontransfected MCF7-S and MCF7-R were incubated with DNM (0.5 μM for 1 h), and then they were used as positive and negative controls of DNM incorporation. Images were detected with a cooled charge-coupled device camera (Micromax; Scientific Instruments, Monmouth Junction, NJ) with a 12-bit detector (RT-EA-1317K; Eastman Kodak, Rochester, NY). A standard rhodamine filter set was used. Analysis was performed using IPLab software (Scanalytics, Fairfax, VA).

Western Blotting. Cells were lysed 72 h after transfection. Nontransfected MCF7-R cells were used as reference of resistant cells. Cells were trypsinized, washed in PBS, counted, and resuspended in radioimmunoprecipitation assay lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 0.5% deoxycholate) containing 5 mM EDTA and protease inhibitors (phenylmethylsulfonyl fluoride, leupeptin, and aprotinin) at the ratio of 100 μl of buffer for 3 × 10^6 cells. After 30 min on ice with some shaking, the lysates were centrifuged at 13,000g for 20 min at 4°C. Protein concentration was determined with a protein assay kit (Sigma, Paris, France). Equal amounts of proteins (20 μg) were mixed with SDS reducing buffer. Protein samples were separated on 7.5% acrylamide SDS-polyacrylamide gel electrophoresis, and then they were transferred onto polyvinylidene difluoride membrane (Hybond-P; GE Healthcare). The membrane was blocked with 5% nonfat dry milk in 0.1% Tween/PBS, and then they were treated with 0.65 μg/ml C219 monoclonal anti-P-gp antibody (Dako Denmark A/S, Glostrup, Denmark) or 2 μg/ml AC-74 monoclonal anti β-actin antibody (Sigma). Detection by enzyme-linked chemiluminescence was performed according to the manufacturer’s protocol (ECL Plus; GE Healthcare). P-gp expression was quantified by NIH Image software (http://rsb.info.nih.gov/ij/).

Reverse Transcription-Polymerase Chain Reaction. Total RNA was extracted (RNeasy kit; QIAGEN) 48 and 72 h after transfection of MCF7-R cells, and cDNA was synthesized using Omniscript reverse transcription kit (QIAGEN) and 0.5 μg/human gene-specific reverse primer of MDR1 or β-actin, which was chosen as an internal control. PCR Master Mix (MBI Fermentas, Hanover, MD) was used for DNA amplification, which was kept in its exponential phase (23 cycles). Primers used for MDR1 amplification (0.5 μM) were as follows: sense, 5′-d(TCTTATTAGGCGACATGGAG-3′) and reverse, 5′-d(AATTGTAGG- CATTGGCTC-3′). The 300-nucleotide amplification was located on exons 12 and 13. Primers for β-actin amplification (0.5 μM) were as follows: sense, 5′-d(ACCAAATGGGACGACATGGAG-3′) and reverse, 5′-d(TCTTATTAGGCGACATGGAG-3′). Amplicon length is 237 nucleotides. Amplification products were separated on a 1.8% agarose gel stained with 6 μg/ml ethidium bromide. Gene expression level was quantified by NIH Image software.

Results

Choice of the Target Site and TFOs. To choose a site to form a stable helix, the MDR1 gene was screened with BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) for oligopurine-oligopyrimidine sequences. In the whole gene, three regions are susceptible to form a stable triple helix: 1) a 12-bp region in exon 2, 2) a 21-bp region in exon 3, and 3) a long sequence of 410 bp in intron 14 (Fig. 1A) (Chen et al., 1990; Pauly et al., 1995). The sequence of exon 2 containing only 12 bp was judged too short in view of the specificity of action of the TFOs. Therefore, the oligopurine-oligopyrimidine sequence located in exon 3 and illustrated in Fig. 1B was chosen as the target for TFOs and DNM conjugates. This sequence contains an inverted site that has to be taken into account during the conception of new and efficient TFOs.

TFOs form Hoogsteen or reverse Hoogsteen hydrogen bonds with the purine-rich strand of the duplex DNA (Buchini and Leumann, 2003). Purine-rich (GA) and mixed purine/pyrimidine (GT) TFOs bind preferentially antiparallel to the purine-rich strand, whereas pyrimidine-rich (TC) TFOs bind parallel. In both parallel and antiparallel triplex motifs, the TFO is located in the major groove of the double helix. GA and GT TFOs form stable triplexes at physiological pH, whereas the ability of TC TFOs to form stable triplexes at neutral pH is very limited, because of the required protonation of the cytosines to form the CG-C+ tetraplets. However, it is possible to introduce chemical modifications in the structure of the oligonucleotide that improve the stability of the formed triplex and allow triplex formation at neutral pH (Buchini and Leumann, 2003).

The TFOs chosen to target the selected sequence in exon 3 are reported in Fig. 1C. Several oligonucleotides, with or without chemical modifications, have been conceived. Four TFOs with (GT) motif were chosen in the aim to avoid pH dependence. The oligonucleotide indicated as GT1 corresponds to the oligonucleotide used in a previous study, and it contains a single base interruption in the purine strand (indicated in bold in the duplex sequence) (Scaggiante et al., 1994). Oligonucleotides GT2 and GT3 encompass together GT1, and they are in the parallel orientation. GT2 covers the region with the single base interruption in the purine strand. GT4 has been chosen to form an antiparallel triplex. Furthermore, (TC) oligonucleotides (directed against box a, Fig. 1) were used, and two types of modifications were introduced to increase triplex stability. In PM, thymidines are substituted by 5-propynyl-deoxyuridine (P) and cytosines by 5-methyldeoxycytidine (M). These two modifications are already known to stabilize the triplex (Duca et al., 2005). Finally, LNA have been studied (Fig. 1D). Oligonucleotides LNA1, LNA2, and LNA3 alternate T, M, LNA-modified thymidines (T in Fig. 1), or cytidines (C in Fig. 1) that have been shown to improve triplex formation at physiological pH (Sun et al., 2004).

Triplex Formation. At first, we studied the ability of the described oligonucleotides to form a triple helix by using both...
gel retardation assays and UV-visible absorbance melting experiments. In our experimental conditions, the (GT) oligonucleotides (GT1–4) are unable to form a triple helix even at high concentrations (10 μM) and long incubation times (up to 48 h). All other chosen oligonucleotides (PM and LNA1–3) are able to form a triple helix, with different efficacies. As shown in Fig. 2, A and B (top), after 2-h incubation at 37°C, oligonucleotide PM was the most efficient in forming the triplex. LNA1 and LNA2 are slightly less efficient, whereas LNA3 has the lowest ability to form the triplex. Figure 2, A and B (bottom), shows the gel retardation assay after 24 h of incubation at 37°C, and we can observe that the efficacy of all oligonucleotides is comparable. These results are summarized in Table 1, where both C_{50} values and melting temperature (T_m) values are reported. Melting temperatures values for all these oligonucleotides do not present relevant differences, but the small variations correspond well to the differences recorded by gel shift assays. Observed values of K_d and T_m are in good agreement with what reported for the same type of modified triplex-forming oligonucleotides in similar experimental conditions (Sun et al., 2004). To further compare these four oligonucleotides, we studied the kinetic of formation of the triple helix over 48 h. As reported in Fig. 3, PM and LNA1 to 3 formed triplexes of comparable stability after 48 h, but the rate of formation is different. Triplex formation is faster for the PM oligonucleotide. Based on these observations, the study was pursued coupling PM and LNA2 oligonucleotides to DNM to perform cellular experiments.

**Synthesis of the Daunomycin-Conjugated TFOs.** PM and LNA2 have been coupled to DNM in 3’ position, leading to conjugates PM-DNM and LNA2-DNM (Fig. 4). The presence of DNM at the 3’ end of the oligonucleotides protects them against exonuclease degradation in cells. Furthermore, it is well established that for pyrimidine triplexes the conjugation in 5’ of DNA intercalators, such as acridine (Sun et al., 1989; Birg et al., 1990) or more recently DNM (Garbesi et al., 1997; Carbone et al., 2004; Napoli et al., 2006), stabilizes triplex formation. For this reason, PM has been coupled to DNM also in 5’ position, resulting in DNM-PM. In the latter case, the oligonucleotide was protected in 3’ position toward exonuclease degradation by introduction of an amino group [(CH₂)₆-NH₂] instead of the terminal phosphate group. As negative control, daunomycin was coupled to the 3’ end of another oligonucleotide (SC) (the sequence is reported under Materials and Methods) that is unable to form a triple helix on the desired MDR1 sequence (conjugate SC-DNM).

For the synthesis of the conjugates, as shown in Fig. 4, TFOs were coupled to an ω-iodoalkyl derivative of daunomycin, whose synthesis was described previously (Capobianco et al., 2005). In the first step, the thiophosphate group of the oligonucleotide is activated by a 0.5 M solution of dithiothreitol and crown ether 18-crown-6 in N,N-dimethylformamide. The coupling is fol-

---

**Fig. 1.** A, potential triplex sites in the MDR1 gene. B, oligopurine-oligopyrimidine sequence within exon 3 of MDR1 gene. The 15-bp target sequence (a) is encircled by a continuous line. A longer 24-bp region containing an inverted site (bold bases) is indicated by a dotted line (b). C, oligonucleotides used to study triplex formation against region a. D, base and sugar modifications used in this study.
lowed by the deprotection of the DNM moiety using a 0.2 M solution of NaOH. After HPLC purification, the product has been obtained in 65% yield over two steps.

Once synthesized, the stability of the formed triplex was evaluated by gel shift assay (Table 2; Supplemental Fig. 1). As expected, the coupling of DNM to the 5′ end of the TFO (DNM-PM) induced a stabilization of the triplex compared with PM alone. This is probably due to the intercalation of the DNM moiety at the 5′ end of the triplex, as observed in previous work with various acridine-conjugated oligonucleotides analogs (Arimondo et al., 2000) and other GT and TC triplex-forming oligonucleotides (Capobianco et al., 2001; Carbone et al., 2004; Napoli et al., 2006). Noteworthy, the triple-helix formation of the studied oligonucleotides analogs (Arimondo et al., 2000) and other GT and TC triplex-forming oligonucleotides (Capobianco et al., 2001; Carbone et al., 2004; Napoli et al., 2006). Noteworthy, the presence of the intercalating agent at the 5′ end of the TFO speeds up triplex formation (Fig. 5). The attachment of the DNM moiety at the 5′ end of the triplex, as observed in previous work with various acridine-TFO conjugates, suggesting marked differences between the 5′ and 3′ triplex/duplex junction (Sun et al., 1989; Arimondo et al., 2000). This destabilization effect is more pronounced for LNA2-DNM (Table 2).

**Cellular Uptake of PM-DNM.** After the synthesis of TFO-DNM conjugates, we turned our attention to their application in the cellular context. The first question we wanted to address was the cellular uptake in MDR1-resistant cells of conjugated DNM compared with free unconjugated DNM. We chose for these experiments to use PM-DNM, which is protected from exonuclease degradation in 3′ by the DNM moiety. To our knowledge, 3′ DNM conjugates have not been studied previously.

MCFS7-S cells (the parental cell), MCFS7-R cells (the doxorubicin-resistant line), parental NIH-3T3, and resistant NIH-MDR-G185 overexpressing the human MDR1 gene were treated for 1 h with 0.5 μM DNM, and then they were examined under a fluorescence microscope. MCFS7-S cells were highly fluorescent, with a predominant accumulation of DNM in the nucleus (Fig. 6A), whereas no fluorescence was observed in MCFS7-R cells. As expected, high cell surface expression of P-gp in resistant MCFS7-R cells leads to DNM efflux. Similar results were obtained with NIH-3T3 and NIH-MDR-G185 cells (data not shown).

After this control experiment, the cellular uptake of 0.5 μM PM-DNM or LNA2-DNM in MCFS7-S cells, MCFS7-R cells, NIH-3T3, and NIH-MDR-G185 cells was followed by fluorescence imaging at 24, 48, and 72 h. Figure 6B shows the results obtained after treatment of MCFS7-R cells with PM-DNM conjugate alone (first column), with PM-DNM conjugate and OFA (a cationic lipid formulation) as transfectant agent (second column), and with PM-DNM conjugate and SuperFect (a cationic dendrimer) as transfectant agent (third

### Table 1

<table>
<thead>
<tr>
<th>Oligonucleotide (5′−3′)</th>
<th>C50 (2 h)</th>
<th>C50 (24 h)</th>
<th>Tm (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GT1</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
<tr>
<td>GT2</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
<tr>
<td>GT3</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
<tr>
<td>GT4</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
<tr>
<td>PM</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
<tr>
<td>LNA1</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
<tr>
<td>LNA2</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
<tr>
<td>LNA3</td>
<td>0.04 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>49 ± 0.5</td>
</tr>
</tbody>
</table>
Because of the important cell mortality observed as soon as 24 h after treatment with LNA2-DNM, we chose PM-DNM to pursue the cellular study. The first remarkable observation derived from the comparison of Fig. 6, A and B, is that PM-DNM conjugate is able to entry in resistant cells, with or without transfectant agent. This shows that, in contrast to DNM alone, the oligonucleotide confers to DNM the ability to overcome cellular resistance (i.e., the efflux activity of the Pg-P pump). Similar results were obtained for NIH-MDR-G185 cells (Supplemental Fig. 2). No significant differences in intensity or intracellular distribution of the DNM-conjugated oligonucleotides were observed between parental and resistant cells. The second noteworthy observation is that the hydrophobicity of the anthraquinone moiety of DNM increases the affinity of the conjugate for the cell membrane and helps the uptake of the conjugates by endocytosis. In fact, even in the absence of a transfectant agent the conjugate is able to enter the cell membrane, a result very difficult to obtain for an oligonucleotide alone. The two moieties that constitute the conjugate, the anthracycline and the TFO, thus act synergistically and favor cell penetration. It is then conceivable that, when coupled to an oligonucleotide, DNM can bypass cell resistance and still exert some form of anticancer effect.

Regarding the cellular distribution of PM-DNM in cells, this is very different from the distribution of DNM. Whereas DNM has been shown to accumulate in nuclei (Fig. 6A), PM-DNM is largely localized in cytoplasm with perinuclear accumulation (Fig. 6B). Furthermore, the presence of fluorescent vesicles can be observed, suggesting the involvement of an endocytic pathway in the internalization of the conjugates (Tonkinson and Stein, 1994; Hu et al., 2002). Whereas anthracyclines quickly accumulate in cell nuclei, and in a smaller proportion in organelles (Rutherford and Willingham, 1993), oligonucleotides initially incorporate into endosomes, and are then localized in the nucleus much later after their release into the cytoplasm. In agreement with our results, 5’ DNM conjugates of an 11-mer (GT) TFO have been shown to accumulate primarily in the cytoplasm of MCF7-S cells in the absence of transfectant (Carbone et al., 2004). We suggest that, in the PM-DNM, the DNM moiety allows cell internalization of the conjugates into parental as well as resistant cells, whereas the oligonucleotide moiety is responsible of the cytoplasmic localization of PM-DNM.

As shown in Fig. 6B, the cell fluorescence intensity 24 h after transfection of PM-DNM into MCF7-R cells in the presence of OFA or SuperFect is comparable with the intensity without transfectant. However, fluorescent speckles are now observable (indicated by an arrow). In the presence of transfectant, some conjugates are trapped in vesicles as reservoirs of PM-DNM, which are released over time. After 48 h, there is an enhancement in the fluorescence intensity of cells that have been transfected in the presence of the transfectant agent. Their speckled pattern is also increased. A cationic lipid-mediated uptake has already been shown in nonresistant cells to increase the intracellular pool of 5’ DNM conjugates (Carbone et al., 2004), with a corresponding increase in nuclear accumulation. Here, we also used a cation dendrimer agent and observed the same effect. Finally, 72 h after transfection, cells are observed at 63× magnification, and nuclear fluorescence is observed when PM-DNM is transfected in the presence of OFA. Nevertheless, the nuclear fluorescence quenching of DNM (DNM fluorescence decreases 20 time after its intercalation in DNA) (Laigle et al., 1996) is a limitation for fluorescence imaging. Microspectrofluorimetry allowed the nuclear localization of PM-DNM as soon as 48 h after transfection with OFA, as confirmed in Fig. 7A. A large
band centered around 596 nm is observable. Very little nuclear accumulation was measured in the absence of OFA. In that case, similar spectra were observed in the cytoplasm and in the nucleus (Fig. 7C, two bands around 560 and 590 nm), which resemble the spectrum recorded in the cytoplasm when the transfecting agent OFA is used (Fig. 7B). DNM presents two major emission maxima at ~560 and ~592 nm (I_{560 nm}/I_{592 nm} = 0.8) (Karukstis et al., 1998). The peak at ~592 nm dramatically increased in the DNM conjugates (the spectrum of PM-DNM in PBS is reported in Fig. 7D for comparison). In contrast, inversion of the 560-nm/592-nm intensity ratio has been observed in relation to doxorubicin degradation (Fiallo et al., 1993). Therefore, the enhancement of the peak at ~560 nm in the cytoplasm when using OFA (Fig. 7B) or in both nucleus and cytoplasm in its absence (Fig. 7C) might indicate a degradation of the conjugate with liberation of free DNM. However we did not succeed to reproduce this potential degradation of the conjugates in vitro in cell lysates or in various cell media in the absence or presence of salmon sperm DNA. It is noteworthy that no free DNM was detected in the nucleus when OFA was used as transfectant (Fig. 7A). In that case, the enlargement of the fluorescence peak observed in the nucleus (Fig. 7A) in comparison with the peak of the conjugate in PBS (Fig. 7D) can result from a 10-nm blue shift that we observe when PM-DNM is incubated in the test tube with cell lysates (data not shown). Similar results were obtained with NIH-MDR-G185 cells and with the nonspecific 3’ DNM conjugate SC-DNM (data not shown).

**Down-Regulation of MDR1 Gene Expression with the Triplex-Forming PM-DNM.** With the experiments described above, we have established that the PM-DNM and DNM-PM conjugates form a stable triplexes on the DNA target (Table 2) and that they are less cytotoxic than LNA2-DNM. Furthermore, when transfected in the presence of OFA, they accumulate in the nucleus of resistant cells, and they are not ejected by the P-gp pump (Figs. 6 and 7). Thus, we wanted to investigate whether the conjugates are able to reach their target (the MDR1 gene) and modulate its expression.

The ability of PM-DNM and DNM-PM to down-regulate the MDR1 expression in MCF7-R cells was studied at the level of the protein and the mRNA by Western blot and RT-PCR, respectively (Fig. 8). An efficient siRNA (si1) (Stierlé et al., 2004, 2005) and an AS (Brigui et al., 2003) directed against MDR1 were chosen as positive controls. SC-DNM (a scrambled control of PM-DNM) and PM-NH2 [PM containing the linker arm (CH2)6-NH2 in 3’ and no DNM] were used as negative controls. We have previously shown that with si1 the decrease in P-gp levels in MCF7-R cells is best followed after 72 h of treatment, whereas the highest reduction in MDR1 mRNA was obtained after 48 h (Stierlé et al., 2004).

**TABLE 2**

<table>
<thead>
<tr>
<th>Oligonucleotide</th>
<th>C50 2 h</th>
<th>C50 24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM-DNM</td>
<td>0.83 ± 0.07</td>
<td>0.19 ± 0.10</td>
</tr>
<tr>
<td>LNA2-DNM</td>
<td>1.0 ± 0.3</td>
<td>0.39 ± 0.09</td>
</tr>
<tr>
<td>DNM-PM</td>
<td>0.38 ± 0.07</td>
<td>0.04 ± 0.01</td>
</tr>
</tbody>
</table>

Fig. 5. Graph reporting the kinetics of the formation of triple helix with the conjugates oligonucleotides over 72 h of incubation at 37°C in 50 mM HEPES, pH 7.2, 50 mM NaCl, and 10 mM MgCl2.

Fig. 6. Fluorescence imaging. A, 0.5 μM DNM in MCF7-S and MCF7-R cells after 1-h incubation (top, fluorescence; bottom, bright field). B, 0.5 μM PM-DNM in MCF7-R cells after 24-, 48-, or 72-h treatment without transfectant or transfected with OFA or with SuperFect.
This 24-h gap results from P-gp long half-life (Nieth et al., 2003; Stierle et al., 2004). Therefore, we studied the effect of the conjugates on mRNA expression after 48 h of treatment and on P-gp levels after 72 h.

All oligonucleotides were used at a concentration of 500 nM, with the exception of si1 that was used at a concentration of 10 nM. Figure 8, A and B, shows the results obtained for P-gp and mRNA expression, respectively. Compared with the reference SC-DNM (unable to form triplex on MDR1 gene), PM-NH₂ caused a slight decrease in P-gp (85% remaining signal), and it had no effect on mRNA (96% remaining signal) expression. Concerning the positive controls, si1 gave, as expected, a very efficient decrease of P-gp levels, with only 30% of signal observed, and mRNA expression (40% remaining). Again, treatment with the positive antisense control AS led to 68% P-gp expression remaining and 36% mRNA expression remaining. Regarding the conjugates, a significant decrease in P-gp expression (46% remaining) and mRNA (64% remaining) was obtained with PM-DNM, whereas DNM-PM gave only 75 and 88%, respectively. The conjugate containing the DNM residue in 3’ position is thus clearly more active in inhibiting MDR1 gene expression than the residue in the 5’ position.

Discussion

Anthracyclines, and in particular DNM, are used for the treatment of a wide range of malignancies, but the emergence of multidrug resistance, as well as myelosuppression and cardio toxicity, limits their effectiveness in the clinic. In this study, we demonstrate that it is possible to specifically target DNM to specific sites on the DNA, by using conjugates of oligonucleotides able to form a triple helix on the DNA and the DNM moiety. Moreover, the conjugation of DNM to the oligonucleotides was shown to improve their cellular uptake, and the DNM conjugates were able to deliver the drug on the MDR1 gene even in DNM-resistant cells. In the literature, DNM has been coupled to several triplex-forming oligonucleotides and in particular to the 5’ end of an 11-mer (GT) TFO, which revealed to be highly specific for its target sequence, leading to reduction of transcription of c-myc in vitro and in cancers cells (Carbone et al., 2004; Napoli et al., 2006). Such 5’ conjugates showed a higher degree of affinity than native oligonucleotides for the oligopyrimidine-oligopurine duplex target, and the presence of the amino sugar of DNM increased such stability (Garbesi et al., 1997). In fact, in the DNM-TFO conjugates, the anthraquinone moiety intercalates in duplex DNA. Once intercalated in DNA, ring D of the anthraquinone protrudes into the major groove of DNA, whereas ring A reaches out into the minor groove. The amino sugar, which is linked to ring A, is therefore located in the minor groove and stabilizes the complex (Frederick et al., 1990).

In this study, we investigated three types of TFOs: 1) (GT)-containing oligonucleotides, 2) PM oligonucleotides (where thymidines have been substituted by P and cytosines...
by M), and 3) LNA-containing oligonucleotides (Fig. 1). We were surprised to find that the (GT) TFOs did not form a triplex helix in our experimental conditions (pH 7.2; 37°C; 100 mM NaCl and 10 mM MgCl₂). The previously studied GT1 was, in fact, shown to form a stable triplex only in the presence of cationic spermidine and at 20°C (Scagghian et al., 1994), conditions that favor triplex formation. In contrast, the pyrimidine chemically modified TFOs (PM and LNA) formed observable triplexes. The kinetics is different for the LNA-modified TFOs and the PM TFO, the latter being faster and more stable (2-fold; Fig. 3; Table 1). Among the LNA TFOs, the most efficient contains 5-methylcytosines instead of cytosines and alternated LNA thymines, starting with a non-LNA base in 5’. This is in agreement with previous observations indicating that the most stable LNA forming triplexes contain alternate LNA thymidines (every two to three bases) and 5-methylcytosines (Sun et al., 2004). Thus, among the eight oligonucleotides studied for their ability to form a triple helix, we found four of them (PM and LNA1–3) suitable to be used in an antigenic approach. We finally chose PM and LNA2 for the conjugation to DNM because they were able to attain 100% of triplex formed rapidly (Figs. 2 and 3). Upon conjugation to DNM at the 3’ end, triplex stability decreased and also the kinetics of formation (Table 2). Coupling to the 5’ end stabilized triplex formation and increased the kinetics, confirming previous reports (Garbesi et al., 1997; Capobianco et al., 2001, 2005). However, the stabilization observed in our study is lower than observed previously. Noteworthy, the experiments are not comparable because, in the literature, in the absence of DNM the TFOs hardly formed a triplex in near physiological conditions, whereas, in our case, the TFO used already forms a very stable triplex on the target site. Thus, we cannot conclude whether there is a lower stabilization effect by DNM than expected and whether the lack of a CpG sequence at the intercalation site, preferred by DNM (Quigley et al., 1980; Capobianco et al., 2001), or structural variations of the triplex induced by the chemical modifications on the TFOs play any role. Concerning the difference in 3’ versus 5’ conjugation, our findings are in agreement with previous reports for acridine and (T,C) TFO conjugates (Sun et al., 1989, 1991). In brief, it has been observed that intercalating agents stabilize triplex formation when attached to the 5’ of pyrimidine TFOs and thus when positioned at the 5’ duplex/triplex junction. Because of the lack of a systematic study on antiparallel triplexes, it is not possible to compare our conjugates to the 5’ DNM-(GT) TFOs (3’ triplex/duplex junction) that were used for cellular studies (Carbone et al., 2004; Napoli et al., 2006).

On the cellular aspect, we observed, interestingly, that the PM-DNM conjugates are able to penetrate in the cells and to remain up to 72 h, in breast cancer-resistant MCF7-R cells and in the mouse fibroblasts NIH-MDR-G185 overexpressing MDRI, cells known to induce DNM efflux by the P-gp pump. It is noteworthy that the amount of fluorescence observed is 2 times higher than that of DNM alone. Therefore, the conjugates are able to enter resistant cells as a result of both the DNM moiety that increases the lipophilicity of TFO and the oligonucleotide moiety that is not recognized by the P-gp pump. The use of transfecants agents increases the penetration efficacy (2.3-fold), and it favors nuclear localization that increases up to 72 h, as described previously for the DNM-(GT) TFO in prostate cancer cells DU145 and PC3 (Carbone et al., 2004). Even if the use of transfactant was necessary to enhance TFO nuclear accumulation of the conjugates and therefore antigenic effect, the fact that these conjugates overcome MDR resistance and are able to enter cells without transfecting agents and to remain up to 72 h makes them interesting tools to deliver DNM in drug-resistant cells, upon use eventually of a cleavable linker between the two entities. By microspectrofluorometry, we monitored the fluorescence spectra in the nucleus and in the cytoplasm of cells. Even if there might be a partial degradation of the conjugate with release of free DNM (as suggested by an enhancement of the shoulder at ~560 nm; Fig. 7), especially in the absence of the transfecting agent, we observe a clear peak at ~590 nm due to the intact conjugate, particularly in the nucleus (Fig. 7A). This intact conjugate is responsible for modulation of the expression of the target MDR1 as observed by RT-PCR and Western blot (Fig. 8).

Noteworthy, in vitro studies showed that conjugation of DNM at the 5’ end of PM (DNM-PM) led to stabilization of the triplex and conjugation at its 3’ end (PM-DNM) to destabilization. In contrast, Western blot and RT PCR analysis revealed that, at the cellular level, PM-DNM is the most efficient: only 46% of MDRI expression was observed, compared with 75% with DNM-PM and 85% with PM-NH2. This is a clear indication that there is not always a correlation between triplex stability in vitro and the biological effect. The results here obtained seem to suggest that the DNM moiety of the conjugates plays an important and active role in the biological effect, regardless of its capacity of stabilizing the triangle helix. The molecular mechanism of action in vivo of DNM is not completely elucidated, although it is known that its intercalation in the DNA double helix plays an essential role in the cytotoxic action. After intercalation, three mechanisms are conceivable: 1) topoisomerase II poisoning, by stabilizing the cleavage complex formed by the enzyme and DNA as amssacrine or epipodophyllotoxins (Baldwin and Osheroff, 2005); 2) DNA alkylation (Swift et al., 2006); and 3) generation of hydroxyl radicals responsible for double-stranded breaks of DNA. Furthermore, other possible mechanisms of action have been proposed recently (Gewirtz, 1999). We tested whether the mechanism of action of the conjugate could be due to sequence-specific topoisomerase II DNA cleavage (Supplemental Fig. 3). No sequence-specific DNA cleavage could be observed due to the action of the conjugates, even if it is clearly seen that the DNM is well positioned at the triplex end (a longer footprint is observed). We also controlled whether the difference could be due to an antisense effect of the TFO that can bind to the purine-rich RNA. We observed, in fact, that the TFOs bind to the RNA purine strand of the target sequence, especially LNA2 (C₅₀ = 0.03 μM ± 0.01; Supplemental Fig. 4). This is not surprising because the LNA chemistry was developed to increase the stability of the antisense oligonucleotides. Finally, DNM-PM also forms a more stable duplex on the RNA purine strand of the target sequence (C₅₀ = 0.04 ± 0.02, 0.06 ± 0.02, and 0.07 ± 0.01 μM for DNM-PM, PM, and PM-DNM, respectively), and this antisense effect cannot account for the inhibition of MDRI that is observed in cells. We also excluded the degradation of DNM-PM conjugate, which is protected in the 3’ by the presence of a (CH₂)₆-NH₂ linker arm; in cells, both conjugates are stable up to 72 h (data not shown). Together, these results indicate, for the first time, an active role of DNM in the biological effect of the conjugates, which it is not related to a pure binding effect, regardless of the mechanism of action.
(e.g., DNA damage, topoisomerase poisoning, or impaired DNA repair). The difference 5' versus 3' can be explained in part by the different way of intercalation of the DNA at the two junctions, and thus a different orientation/availability of the drug for its action, with the 5' junction being perhaps more prone to intercalation. The neighboring sequences may also influence the activity of DNA (AT/AT in 5' versus ACC/TGG in 3'); it has been shown, for example, that DNA lesions are induced principally 5' of GpC (Swift et al., 2006).

In conclusion, we found that upon conjugation between the anticancer drug DNA and MDR1-directed TFOs it is possible to 1) bypass multidrug resistance, render DNA conjugates immune to P-gp action (oligonucleotide action); 2) favor principally 5'/H11032 has been shown, for example, that DNM lesions are induced by daunorubicin-conjugated triple-helix-forming oligonucleotides targeting the c-myc gene in prostate cancer cells. Nucleic Acids Res 34:734–744.


Address correspondence to: Dr. Paola B. Arimondo, Unite Mixte de Recherches 5153 Centre National de la Recherche Scientifique-MNHN UMS0503, Institut National de la Sante et de la Recherche Medecale UR566, 43 rue Cuvier, 75005 Paris, France. E-mail: arimondo@mnhn.fr

References


